⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OGEN News
Oragenics Inc.
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
globenewswire.com
OGEN
Form 8-K
sec.gov
OGEN
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
globenewswire.com
OGEN
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
globenewswire.com
OGEN
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
globenewswire.com
OGEN
Form 8-K
sec.gov
OGEN
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
globenewswire.com
OGEN
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
globenewswire.com
OGEN
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
globenewswire.com
OGEN
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
globenewswire.com
OGEN